Tag: Cancer Immunotherapy

Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review

Immune-related adverse events (irAEs) are toxicities resulting from use of immune checkpoint inhibitors (ICIs) These side effects persist in some patients despite withholding therapy and using immunosuppressive and immune-modulating agents . The most common ICIs delivered were pembrolizumab (24%) and nivolumabs (37%) Most patients (75%) had metastatic disease and the primary cancer site was melanoma… Continue reading Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review

AACR-AHNS Head and Neck Cancer Conference: Highlights from the Cutting Edge 

Across the surfaces of your mouth, throat, and nasal sinuses, layers of flat cells called squamous cells protect the underlying tissues from injury and pathogens. While these guardian cells are crucial to preserve the function of the tissues they defend, factors such as aging, tobacco, environmental pollutants, and infections can damage the squamous cells, potentially… Continue reading AACR-AHNS Head and Neck Cancer Conference: Highlights from the Cutting Edge 

Patient-reported outcomes in CD30-directed CAR-T cells against relapsed/refractory CD30+ lymphomas

Chimeric antigen receptor (CAR)-T cells targeting CD30 have demonstrated high response rates with durable remissions observed in a subset of patients with relapsed/refractory CD30+ hematologic malignancies, particularly classical Hodgkin lymphoma. This therapy has low rates of toxicity including cytokine release syndrome with no neurotoxicity observed in our phase 2 study. We collected patient-reported outcomes (PROs)… Continue reading Patient-reported outcomes in CD30-directed CAR-T cells against relapsed/refractory CD30+ lymphomas

Valproic acid increases CAR T cell cytotoxicity against acute myeloid leukemia

Only limited efficacy of chimeric antigen receptor T (CAR-T) cell therapy is observed in acute myeloid leukaemia (AML) patients . CD123 and CLL-1 were highly expressed on AML cells . The proportions of T cell subsets and NK cells involved in anti-tumour processes in patients significantly decreased when compared with healthy donors . A possible… Continue reading Valproic acid increases CAR T cell cytotoxicity against acute myeloid leukemia

From the Bench: Creative Approaches in Cancer Research

Improved patient outcomes come from new treatments. New treatments stem from successful clinical trials. Clinical trials build on discoveries made in the lab. And laboratory discoveries? Those rely on a vast array of assays and specialized technologies, combined with the ingenuity of bench scientists who devise, master, and apply these tools in creative ways to… Continue reading From the Bench: Creative Approaches in Cancer Research

Cancer‐associated fibroblasts contribute to the immunosuppressive landscape and influence the efficacy of the combination therapy of PD‐1 inhibitors and antiangiogenic agents in hepatocellular carcinoma

Cancer-associated fibroblasts (CAFs) play a key role in HCC TME remodeling . The level of abundance of CAFs may significantly affect the prognosis and outcome in patients . Patients in the CAF high cluster had a higher levels of inflammatory cell infiltration and a more significant immunosuppressive microenvironment .

Cancer‐associated fibroblasts contribute to the immunosuppressive landscape and influence the efficacy of the combination therapy of PD‐1 inhibitors and antiangiogenic agents in hepatocellular carcinoma

Cancer-associated fibroblasts (CAFs) play a key role in HCC TME remodeling . The level of abundance of CAFs may significantly affect the prognosis and outcome in patients . Patients in the CAF high cluster had a higher levels of inflammatory cell infiltration and a more significant immunosuppressive microenvironment .

A phase 2 study of neoadjuvant chemotherapy plus durvalumab in resectable locally advanced head and neck squamous cell carcinoma

Abstract Background Patients with locally advanced head and neck squamous cell cancer (HNSCC) are treated with surgery followed by adjuvant (chemo) radiotherapy or definitive chemoradiation, but recurrence rates are high. Immune checkpoint blockade improves survival in patients with recurrent/metastatic HNSCC; however, the role of chemo-immunotherapy in the curative setting is not established. Methods This phase… Continue reading A phase 2 study of neoadjuvant chemotherapy plus durvalumab in resectable locally advanced head and neck squamous cell carcinoma

Determinants of overall survival in patients with metastatic uveal melanoma

Despite improvements in the treatment of primary uveal melanoma, patients with metastatic disease continue to exhibit poor survival rates . Use of immune checkpoint inhibitors, such as anti-CTLA-4 and anti–PD-1 therapies, were associated with improved survival outcomes . Development of extrahepatic-only metastases, better baseline performance status, and female sex contributed to a more than 2-fold… Continue reading Determinants of overall survival in patients with metastatic uveal melanoma